RELMADA THERAPEUTICS, INC. (RLMD): Results of Operations and Financial Condition
RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030099301ex99-1.htm PRESS RELEASE DATED AUGUST 6, 2026, REGARDING A CORPORATE UPDATE AND REPORTING ITS FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026 Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Busin
How this was made
The 30-second read
Why it matters
The disclosure combines (1) a cash runway update, (2) specific planned regulatory milestones for both programs, and (3) a leadership change, which together can shift perceived probability-weighted timelines and near-term risk for RLMD.
Market read
Traders can update RLMD’s risk model around FDA/IND timing, manufacturing/CMC execution, and cash runway through 2029 based on the Q2 8-K details.
What to watch
R&D expense rose sharply in Q2 due to higher NDV-01 and sepranolone study and manufacturing/storage costs, which may pressure valuation even with a longer cash runway.
Background
Relmada is a clinical-stage biotech advancing NDV-01 (sustained-release intravesical gemcitabine/docetaxel) and sepranolone, and this 8-K provides Q2 financials plus execution milestones toward IND filings.
Ticker impact
Relmada reports Q2 results and updates that it expects NDV-01 and sepranolone IND filings by year-end 2026, with Phase 3 RESCUE initiation after IND clearance.
Moderate upside bias into the next IND-related milestones, with volatility around FDA alignment and manufacturing/CMC progress.
The filing is a primary disclosure (8-K with exhibit) including cash balance, expense drivers, and specific planned regulatory/clinical timing, which can re-rate biotech risk and runway expectations.
Market effects
Biotech investors may re-focus on clinical-stage intravesical oncology and CNS programs where CMC progress and IND timing reduce perceived regulatory risk.
Primarily US small-cap biotech sentiment via Russell index additions effective June 26, 2026.
Limited direct global spillover; could marginally affect sentiment for similar development-stage oncology/CNS drugmakers.
Counterpoint
Year-end IND timing is still conditional on FDA clearance; any CMC or formulation issues could push milestones and increase burn.
Key entities
- companyRelmada Therapeutics, Inc.
Clinical-stage biotech advancing NDV-01 and sepranolone; filed an 8-K with Q2 results and business update.
- programNDV-01
Sustained-release intravesical formulation of gemcitabine and docetaxel for NMIBC; planned US IND by year-end 2026 and Phase 3 RESCUE initiation after IND clearance.
- programsepranolone
Program with formulation development complete; planned US IND by year-end 2026 and Phase 2 proof-of-concept initiation in Prader-Willi Syndrome after IND clearance.
- executiveBipin Dalmia
Appointed Chief Business Officer during the quarter.